Cav 3.2 inhibitor 1 

Cav 3.2 inhibitor 1 is a T-type calcium channel inhibitor with little binding affinity to dopamine D2 receptors. Cav 3.2 inhibitor 1 can be used for the research of somatic and visceral pain^[1].

Cav 3.2^[1]

Cav 3.2 inhibitor 1 (compound 3a, 0.3 μM) inhibits Cav3.2 activities by about 50% in Cav3.2-transfected HEK293 cells^[1].
Cav 3.2 inhibitor 1 (1 and 10 μM) displays little binding affinity to D2 receptors^[1].
Cav 3.2 inhibitor 1 (0.01-1 μM) inhibits T-currents in Cav3.1-expressing HEK293 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cav 3.2 inhibitor 1 (compound 3a, 10 mg/kg, i.p.) suppresses Cav3.2-dependent somatic and visceral pain in mice^[1].
Cav 3.2 inhibitor 1 (8 nmol/mouse, i.c.v.) has no effect on long-lasting catalepsy in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

481.67

C₃₂H₃₉N₃O

2878598-59-3

O=C1N(CCCCC2=CC=CC=C2)C3=CC=CC=C3N1C4CCN(CCCCC5=CC=CC=C5)CC4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yoshihito Kasanami, et al. Discovery of pimozide derivatives as novel T-type calcium channel inhibitors with little binding affinity to dopamine D 2 receptors for treatment of somatic and visceral pain. Eur J Med Chem. 2022 Aug 27;243:114716.  [Content Brief]